Collectively, these findings identify DDB2 as a novel molecular target of lapatinib and demonstrate that lapatinib can disrupt the DNA-binding capacity of DDB2, promote its degradation, and enhance chemosensitivity in cancers with high DDB2 expression. This evidence concerns the gene DDB2 and cancer.